An analysis finds that mortality rates for NSCLC are falling faster than incidence rates, which the authors attributed to the introduction of targeted therapies in 2013.
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
How to explain adjustments to cancer care due to the COVID-19 pandemic and ease patients’ fears about the impact of those changes.
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.
When should women begin getting mammograms? Guidance can vary based on an individual’s family history or other high-risk identifiers, but physicians advise that women get screened for breast cancer consistently by at least age 50. However, a recent study out of the United Kingdom suggests that starting breast cancer screenings earlier could have a large…
Localized prostate cancer is thought to metastasize by tapping into a developmental program used by its embryonic ancestors.
Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
Engineered cytokine evades the tumor’s defenses and boosts the production of stem-like polyfunctional T cells.
Dr Sue Yom discusses the evolution and future of stereotactic body radiotherapy.
Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments.
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
The assay may play a role in determining use of other treatments like PARP inhibitors.
Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.
There is evidence to support the role of metastasectomy in providing patients with mRCC an improvement in certain clinical outcomes.
Researchers suggest a less-is-more approach may be better than relying on “big data” when deciding on treatment at point of care.